These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17158392)

  • 1. How much will Herceptin really cost? The money is already there.
    Minhas R
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158392
    [No Abstract]   [Full Text] [Related]  

  • 2. How much will Herceptin really cost? Balancing local and national priorities is not new.
    Dillon A; Littlejohns P
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158393
    [No Abstract]   [Full Text] [Related]  

  • 3. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 4. Raising money for herceptin.
    Harrison J
    Nurs N Z; 2007 Mar; 13(2):3. PubMed ID: 17429882
    [No Abstract]   [Full Text] [Related]  

  • 5. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 7. Making a case for a $2700-a-month drug.
    Sibbald B
    CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
    [No Abstract]   [Full Text] [Related]  

  • 8. The hype over herceptin.
    Fitzpatrick J
    Nurs N Z; 2009 Mar; 15(2):4-5. PubMed ID: 19554708
    [No Abstract]   [Full Text] [Related]  

  • 9. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 11. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
    Isaacs RJ; Frampton CM; Kuper-Hommel MJ
    N Z Med J; 2007 Aug; 120(1259):U2676. PubMed ID: 17721579
    [No Abstract]   [Full Text] [Related]  

  • 12. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 13. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmaceuticals can be cost-effective in the long run].
    Jönsson B; Wilking N
    Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
    [No Abstract]   [Full Text] [Related]  

  • 15. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
    Offerhaus L
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
    [No Abstract]   [Full Text] [Related]  

  • 16. Why have evidence if it's really money that matters?
    Walsh C
    Nurs N Z; 2008 Aug; 14(8):2. PubMed ID: 18822549
    [No Abstract]   [Full Text] [Related]  

  • 17. Trust's refusal to fund trastuzumab was "arbitrary".
    Dyer C
    BMJ; 2006 Apr; 332(7544):747. PubMed ID: 16575068
    [No Abstract]   [Full Text] [Related]  

  • 18. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
    Smith M
    J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 20. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.